SI3886813T1 - Farmacevtske formulacije analogov ciklosporina - Google Patents
Farmacevtske formulacije analogov ciklosporinaInfo
- Publication number
- SI3886813T1 SI3886813T1 SI201930510T SI201930510T SI3886813T1 SI 3886813 T1 SI3886813 T1 SI 3886813T1 SI 201930510 T SI201930510 T SI 201930510T SI 201930510 T SI201930510 T SI 201930510T SI 3886813 T1 SI3886813 T1 SI 3886813T1
- Authority
- SI
- Slovenia
- Prior art keywords
- pharmaceutical formulations
- cyclosporine analogs
- cyclosporine
- analogs
- formulations
- Prior art date
Links
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical class CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862771453P | 2018-11-26 | 2018-11-26 | |
| EP19821392.8A EP3886813B1 (en) | 2018-11-26 | 2019-11-22 | Pharmaceutical formulations of cyclosporine analogs |
| PCT/US2019/062849 WO2020112562A1 (en) | 2018-11-26 | 2019-11-22 | Pharmaceutical formulations of cyclosporine analogs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3886813T1 true SI3886813T1 (sl) | 2023-05-31 |
Family
ID=68916602
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201930510T SI3886813T1 (sl) | 2018-11-26 | 2019-11-22 | Farmacevtske formulacije analogov ciklosporina |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US20200163876A1 (sl) |
| EP (1) | EP3886813B1 (sl) |
| JP (1) | JP7489385B2 (sl) |
| KR (1) | KR20210099038A (sl) |
| CN (1) | CN113194927B (sl) |
| AR (1) | AR117150A1 (sl) |
| AU (1) | AU2019386859A1 (sl) |
| BR (1) | BR112021009967A2 (sl) |
| CA (1) | CA3120015A1 (sl) |
| CY (1) | CY1126071T1 (sl) |
| DK (1) | DK3886813T3 (sl) |
| ES (1) | ES2942473T3 (sl) |
| FI (1) | FI3886813T3 (sl) |
| HR (1) | HRP20230548T1 (sl) |
| HU (1) | HUE061877T2 (sl) |
| IL (1) | IL283286A (sl) |
| LT (1) | LT3886813T (sl) |
| MX (1) | MX2021006010A (sl) |
| PH (1) | PH12021551086A1 (sl) |
| PL (1) | PL3886813T3 (sl) |
| PT (1) | PT3886813T (sl) |
| RS (1) | RS64239B1 (sl) |
| SG (1) | SG11202105336TA (sl) |
| SI (1) | SI3886813T1 (sl) |
| SM (1) | SMT202300139T1 (sl) |
| TW (1) | TWI844585B (sl) |
| WO (1) | WO2020112562A1 (sl) |
| ZA (1) | ZA202103090B (sl) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12022552089A1 (en) | 2020-02-19 | 2023-11-20 | Hepion Pharmaceuticals Inc | Use of cyclosporine analogues for treating fibrosis |
| CA3172368A1 (en) | 2020-02-25 | 2021-09-02 | Hepion Pharmaceuticals, Inc. | Use of cyclosporine analogues for treating cancer |
| AU2021388171A1 (en) * | 2020-11-29 | 2023-06-22 | Hepion Pharmaceuticals, Inc. | Use of cyclosporine analogues as antithrombotic agents |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0148748B1 (ko) * | 1988-09-16 | 1998-08-17 | 장 크라메르, 한스 루돌프 하우스 | 사이클로스포린을 함유하는 약학조성물 |
| GB9113872D0 (en) * | 1991-06-27 | 1991-08-14 | Sandoz Ag | Improvements in or relating to organic compounds |
| US6262022B1 (en) * | 1992-06-25 | 2001-07-17 | Novartis Ag | Pharmaceutical compositions containing cyclosporin as the active agent |
| CA2313024C (en) * | 1997-12-10 | 2008-06-03 | Severson, Mary L. | Pharmaceutical compositions containing an omega-3 fatty acid oil |
| US20030216303A1 (en) * | 1998-03-06 | 2003-11-20 | Michael Ambuhl | Emulsion preconcentrates containing cyclosporin or a macrolide |
| ID25908A (id) * | 1998-03-06 | 2000-11-09 | Novartis Ag | Prakonsentrat-prakonsentrat emulsi yang mengandung siklosporin atau makrolida |
| WO2001028518A1 (de) | 1999-10-20 | 2001-04-26 | Vesifact Ag | Cyclosporine enthaltende mikroemulsion-prekonzentrate und mikroemulsionen |
| BR0210505A (pt) | 2001-06-21 | 2004-05-18 | Pfizer Prod Inc | Formulações auto-emulsionantes de inibidores da proteìna de transferência de ésteres de colesterilo |
| JP2005506990A (ja) * | 2001-10-19 | 2005-03-10 | アイソテクニカ インコーポレーテッド | 新規のシクロスポリン類似体のマイクロエマルションプレコンセントレート |
| TW201902507A (zh) | 2017-04-14 | 2019-01-16 | 美商康特維爾製藥公司 | 治療病毒感染之組合療法 |
-
2019
- 2019-11-22 HR HRP20230548TT patent/HRP20230548T1/hr unknown
- 2019-11-22 SG SG11202105336TA patent/SG11202105336TA/en unknown
- 2019-11-22 DK DK19821392.8T patent/DK3886813T3/da active
- 2019-11-22 EP EP19821392.8A patent/EP3886813B1/en active Active
- 2019-11-22 CN CN201980077553.8A patent/CN113194927B/zh active Active
- 2019-11-22 TW TW108142503A patent/TWI844585B/zh active
- 2019-11-22 PL PL19821392.8T patent/PL3886813T3/pl unknown
- 2019-11-22 RS RS20230417A patent/RS64239B1/sr unknown
- 2019-11-22 KR KR1020217019811A patent/KR20210099038A/ko not_active Ceased
- 2019-11-22 AU AU2019386859A patent/AU2019386859A1/en not_active Abandoned
- 2019-11-22 WO PCT/US2019/062849 patent/WO2020112562A1/en not_active Ceased
- 2019-11-22 AR ARP190103428A patent/AR117150A1/es not_active Application Discontinuation
- 2019-11-22 US US16/693,051 patent/US20200163876A1/en not_active Abandoned
- 2019-11-22 SI SI201930510T patent/SI3886813T1/sl unknown
- 2019-11-22 FI FIEP19821392.8T patent/FI3886813T3/fi active
- 2019-11-22 PT PT198213928T patent/PT3886813T/pt unknown
- 2019-11-22 CA CA3120015A patent/CA3120015A1/en active Pending
- 2019-11-22 HU HUE19821392A patent/HUE061877T2/hu unknown
- 2019-11-22 SM SM20230139T patent/SMT202300139T1/it unknown
- 2019-11-22 LT LTEPPCT/US2019/062849T patent/LT3886813T/lt unknown
- 2019-11-22 BR BR112021009967-0A patent/BR112021009967A2/pt unknown
- 2019-11-22 MX MX2021006010A patent/MX2021006010A/es unknown
- 2019-11-22 ES ES19821392T patent/ES2942473T3/es active Active
- 2019-11-22 JP JP2021529703A patent/JP7489385B2/ja active Active
-
2021
- 2021-05-07 ZA ZA2021/03090A patent/ZA202103090B/en unknown
- 2021-05-07 PH PH12021551086A patent/PH12021551086A1/en unknown
- 2021-05-19 IL IL283286A patent/IL283286A/en unknown
-
2023
- 2023-06-22 CY CY20231100293T patent/CY1126071T1/el unknown
- 2023-08-17 US US18/451,456 patent/US20230390198A1/en not_active Abandoned
- 2023-08-17 US US18/451,467 patent/US20230390199A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX2021006010A (es) | 2021-09-21 |
| PL3886813T3 (pl) | 2023-06-19 |
| JP7489385B2 (ja) | 2024-05-23 |
| CN113194927B (zh) | 2023-10-27 |
| ES2942473T3 (es) | 2023-06-01 |
| DK3886813T3 (da) | 2023-05-01 |
| PT3886813T (pt) | 2023-04-26 |
| EP3886813B1 (en) | 2023-03-22 |
| PH12021551086A1 (en) | 2022-01-03 |
| TWI844585B (zh) | 2024-06-11 |
| IL283286A (en) | 2021-07-29 |
| RS64239B1 (sr) | 2023-06-30 |
| CA3120015A1 (en) | 2020-06-04 |
| JP2022513635A (ja) | 2022-02-09 |
| US20200163876A1 (en) | 2020-05-28 |
| US20230390199A1 (en) | 2023-12-07 |
| HRP20230548T1 (hr) | 2023-08-04 |
| KR20210099038A (ko) | 2021-08-11 |
| AR117150A1 (es) | 2021-07-14 |
| HUE061877T2 (hu) | 2023-08-28 |
| US20230390198A1 (en) | 2023-12-07 |
| CN113194927A (zh) | 2021-07-30 |
| BR112021009967A2 (pt) | 2021-08-17 |
| SG11202105336TA (en) | 2021-06-29 |
| SMT202300139T1 (it) | 2023-07-20 |
| ZA202103090B (en) | 2023-09-27 |
| EP3886813A1 (en) | 2021-10-06 |
| CY1126071T1 (el) | 2023-11-15 |
| AU2019386859A1 (en) | 2021-05-27 |
| FI3886813T3 (fi) | 2023-05-04 |
| LT3886813T (lt) | 2023-04-11 |
| TW202038911A (zh) | 2020-11-01 |
| WO2020112562A1 (en) | 2020-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL279464A (en) | Pharmaceutical formulation of odevixibat | |
| IL258464A (en) | Pharmaceutical compositions for oral administration of peptide drugs | |
| IL275639A (en) | Formulation for RNA administration | |
| ZA201908454B (en) | Solid preparation of cariprazine for oral administration | |
| IL312218B2 (en) | Preparations for oral administration of active ingredients | |
| SG11202109102PA (en) | Pharmaceutical formulations | |
| IL283450A (en) | capsule formulations | |
| ZA202006570B (en) | Pharmaceutical formulations | |
| IL283286A (en) | Pharmaceutical formulations of cyclosporine analogs | |
| IL267279A (en) | Pharmaceutical formulations of suvorexant | |
| IL283593A (en) | Bernaflam oral preparations | |
| EP3506947A4 (en) | PHARMACEUTICAL FORMULATIONS OF REGADENOSONE | |
| SG11202010792TA (en) | Improved pharmaceutical formulations | |
| IL271908A (en) | Over-compressed pharmaceutical preparations | |
| ZA201705329B (en) | Pharmaceutical formulations of racecadotril | |
| HK40101429A (en) | Formulations for oral administration of active agents | |
| HK40101653A (en) | Formulations for oral administration of active agents | |
| ZA202212663B (en) | Pharmaceutical formulations | |
| IL308250A (en) | Pharmaceutical formulations | |
| GB202112820D0 (en) | Pharmaceutical formulations | |
| HK40075060A (en) | Pharmaceutical formulations of tenofovir alafenamide | |
| GB202003108D0 (en) | Pharmaceutical formulations | |
| GB2569616B (en) | Sustained release oral pharmaceutical compositions of dicycloverine | |
| HK40014181A (en) | Pharmaceutical formulations of suvorexant |